Short telomeres are associated with aging and agerelated diseases. Our aim was to determine whether short leukocyte telomere length is associated with risk factors and cardiovascular diseases in a high-risk hypertensive population. We measured leukocyte telomere lengths at recruitment in 1271 subjects with hypertension and left ventricular hypertrophy (LVH) participating in the Lifestyle Interventions and Independence for Elders (LIFE) study. At baseline, short mean telomere length was associated with coronary artery disease in males (odds ratio (OR) 0.61, 95% confidence interval (CI) 0.39-0.95), and transient ischemic attack in females (OR 0.62 95% CI 0.39-0.99). Proportion of short telomeres (shorter than 5 kb) was associated with Framingham risk score (r ¼ 0.07, Po0.05), cerebrovascular disease (OR 1.18, 95% CI 1.01-1.15) and type 2 diabetes in men (OR 1.07, 95% CI 1.02-1.11). During follow-up, proportion of short telomeres was associated with combined cardiovascular mortality, stroke or angina pectoris (hazard ratio 1.04, 95% CI 1.01-1.07). Telomere length was not associated with smoking, body mass index, pulse pressure or selfreported use of alcohol. Our data suggest that reduced leukocyte telomere length is associated with cardiovascular risk factors and diseases as well as type 2 diabetes, and is a predictor of cardiovascular disease in elderly patients with hypertension and LVH.
Introduction
Telomeres are located at the ends of chromosomal DNA. They are composed of thousands of tandem repeats of the TTAGGG sequence and associated protein. 1, 2 Telomeres participate in the maintenance of genomic and cellular stability and replication. Telomeres shorten with repeated cell division, and when a critical telomere length is reached the cell enters senescence followed by apoptosis. Therefore, telomeres are considered as a potential biological clock. 3, 4 Telomeres, mostly measured in the DNA of circulating leukocytes, shorten with age. In all populations studied telomeres were shorter in age-matched males than in females, except in the very old. 5 Shorter telomeres than in age-and sex-matched healthy control subjects have been reported in patients with inflammatory and cardiovascular diseases such as rheumatoid arthritis, 6 coronary artery disease, 7 stroke 8 and hypertension. 9 We recently observed that short leukocyte telomeres are predictive of progression of renal disease in patients with type 1 diabetes. 10 Whether accelerated telomere shortening is a primary or secondary phenomenon in such diseases is not clear.
In the LIFE study, patients with hypertension and left ventricular hypertrophy (LVH) by electrocardiography criteria were randomized in a double-blind study to treatment based on atenolol or losartan. 11 The main results were 25% reductions in stroke and new-onset diabetes in the losartan-based treatment group compared with the atenolol-based group. In a post hoc substudy, we measured the leukocyte telomere length of 1271 patients from the LIFE study using the Southern blot method. We report associations of telomere length with cardiovascular disease and type 2 diabetes.
Methods
Patients and study design The LIFE study randomized 9193 patients aged 55-80 years with hypertension and signs of LVH on electrocardiogram (according to Cornell voltage duration or Sokolow-Lyon voltage criteria) to losartan-based versus atenolol-based treatment after 1-2 weeks of placebo if they had sitting blood pressure of 160-200/95-115 mm Hg. Patient follow-up lasted for at least 4 years with regular visits. The main outcome and the study design, organization, clinical measures and endpoint definitions have been published.
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The primary end point was a composite of the first occurrence of cardiovascular death, stroke or myocardial infarction. Other pre-specified outcomes were total mortality, angina pectoris or heart failure requiring hospitalization, resuscitated cardiac arrest and new-onset diabetes. End points were adjudicated by an independent endpoint committee.
Patients gave written informed consent, and the study protocol was approved by relevant ethics committees. An independent data and safety board monitored the study. Permission to use DNA samples from Finnish patients for scientific purposes was obtained by informed consent from patients under a protocol approved by the ethics committee of the Finnish National Institute of Health.
The LIFE study is registered at http://www. clinicaltrials.org as NCT00338260.
Measurement of telomere length
Samples of peripheral venous EDTA blood for isolation of DNA were obtained at the start of the study and stored frozen until isolation of DNA at the Clinical Material Group, Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden. Extraction of DNA from EDTA blood was performed using PureGene KIT (Gentra Systems, Minneapolis, MS, USA).
For this study, DNA samples of 1271 Finnish study participants (668 women and 603 men) were chosen as they represented a sufficiently large cohort from a population that was relatively homogenous genetically, socioeconomically and culturally.
Telomere length was measured as described previously 10 using TeloTAGGG Telomere length assay kits (Roche Molecular Biochemicals, Basel, Switzerland). In brief, an aliquot (1 mg) of DNA (sample or control DNA) was digested with HinfI and RsaI (20 U per mg DNA each; Roche Molecular Biochemicals) at 37 1C for 2 h. The separation of digested DNA was performed by 0.8% agarose gel electrophoresis at 5 V cm À1 in 0.04 M Tris-acetate, 0.001 M EDTA, pH 8.0 buffer for 2-3 h.
After electrophoresis, the DNA fragments were transferred by Southern blotting (by capillary transfer) to a positively charged nylon membrane (Hybond N þ , Amersham, Little Chalfont, UK) at room temperature using 3 M NaCl and 0.3 M sodium citrate, pH 7.0. The transferred DNA was then fixed on the blotting membrane by ultraviolet crosslinking (UV Stratalinker 1800, Stratagene, La Jolla, CA, USA).
The blotted DNA fragments were hybridized to a digoxigenin-labeled probe specific for telomeric repeats in a hybridization oven (Techne, Burlington, NJ, USA) at 42 1C for 3 h.
The membrane was incubated with a digoxigeninspecific antibody covalently coupled to alkaline phosphatase and then visualized by virtue of alkaline phosphatase-metabolizing CDP-Star (Roche Molecular Biochemicals), a highly sensitive chemiluminescence substrate. The membrane was then exposed to a hyperfilm ECL (Amersham). Films were analyzed using Adobe PhotoShop and Science Lab 99 Image gauge software (Fuji Photo Film Co, Ltd, Tokyo, Japan).
Mean size of the telomere restriction fragment was estimated using the formula {sum}(OD i Àback-ground)/{sum}(OD i Àbackground/L i ), where ODi is the chemiluminescent signal and L i is the length of the telomere restriction fragment at position i. Interassay coefficient of variation was 3.70% when calculated from an internal control DNA sample in 96 assays.
There is increasing evidence suggesting that regardless of mean telomere length, one critically short telomere may cause a cell to enter senescence. 12, 13 Therefore, using the same films as for mean telomere restriction fragment analysis, we also calculated the percentage of short telomeres (shorter than 5 kb) in each telomeric sample. This cutoff value was chosen as it identified the shortest 15% of telomeric DNA. Briefly, the total chemiluminescence intensity of each sample was measured and the signal intensity below molecular size marker 5 kb was quantified. Percentage of short telomeres ¼ (intensity of chemiluminescence signal below 5 kbÀbackground) Â 100/(total signal intensityÀ background).
Statistical methods and analysis
All analyses were conducted first separately in men and women and then in the pooled data. Disease prevalences at baseline were analyzed by computing odds ratios (ORs) using logistic regression models. Age and in the pooled analyses sex were adjusted for by including these variables as covariates in the models. Disease incidences were analyzed by computing hazard ratios using the Cox proportional hazard model. Subjects were followed up from baseline examination to event, death or other termination of the follow-up or the end of the Telomere length in the LIFE studyfollow-up on 16 September 2001. Age was adjusted for by including it into the model as a covariate, and, additionally, sex was used in the pooled analyses as a strata variable allowing calculation of baseline hazards in men and women. Proportional hazard assumptions were tested for telomere log-length and proportion of short telomeres separately in men and women using Schoenfeld residuals and were found not to be violated for any disease outcome (P-values 0.28-0.97). Table 1 shows mean telomere length, proportion of short telomeres (o5.0 kb) and baseline characteristics of the study population. Men had shorter mean telomere length (8.1 ± 0.81 kb, mean ± s.d.) and higher proportion of short telomeres (8.7±4.5%, mean ± s.d.) compared with women (8.2 ± 0.80 kb and 7.9 ± 4.6%, respectively). Mean telomere length showed wide individual variation, and annual telomere shortening rate was similar in males and females ( Figure 1 ). Because only one measurement was perfomed, the change in telomere length was calculated using age at the time of drawing the relevant blood sample. Mean telomere length was inversely correlated with proportion of short telomeres ( Figure 2) .
Results
Disease prevalence at baseline and disease incidence during follow-up are shown in Table 2 . At baseline, proportion of short telomeres, but not mean telomere length, correlated with Framingham risk score and serum glucose (men only, Table 3 ). In this context, the problem of 'mass significance' should be considered, notably when significances are modest or weak. Also at baseline, OR for disease prevalence versus mean telomere length was associated with angina pectoris and ischemic heart disease in males, and with transient ischemic attack in females (Table 4) . Proportion of short telomeres (shorter than 5 kb) was associated with type 2 diabetes (not significant in females), cerebrovascular accidents and with any cardiovascular disease at baseline (Table 4) . Surprisingly, mean telomere length was positively associated with myocardial infarction in females, but the number of cases was low (Table 2) .
Telomere length was not significantly associated with body mass index (BMI), systolic or diastolic blood pressure, pulse pressure, proteinuria (Table 3) , smoking or self-reported use of alcohol (data not shown). Moreover, telomere length was not associated with electrocardiogram estimation of LVH by Cornell or Sokolow-Lyon criteria (data not shown).
During follow-up, development of angina pectoris in men was associated with short mean telomere length ( Table 5 ). Development of any cardiovascular disease during follow-up was associated with proportion of short telomeres in the whole study group. Outcomes of drug treatment based on either losartan or atenolol were not affected by telomere length at baseline.
Discussion
Our observation of an association of short mean telomere length with previous transient ischemic attack (in women) has not been reported previously. Similar to our observation of an association of cerebrovascular accidents with proportion of short Telomere length in the LIFE studytelomeres (Table 4) , it is in agreement with the reported association of telomere length with stroke. 8 It also fits previous observations of an association between short telomeres and cardiovascular diseases such as carotid artery atherosclerosis, 14 coronary artery disease 7 and myocardial infarction. 15 Our findings support the concept that short telomeres may represent premature vascular aging with increased risk of cardiovascular disease. 3,4 Short telomere length was associated with ischemic heart disease in males only. This gender difference may be explained by differences by gender in clinical symptoms or by small patient numbers. The positive association of telomere length with prevalence of myocardial infarction at baseline observed in females, with OR 2.55 (not significant in males, Table 4 ), is surprising and may be a chance finding due to the low number of events.
Proportion of short telomeres and risk factors
Interestingly, we noticed that proportion of short telomeres (shorter than 5 kb), but not mean telomere length, was associated with Framingham risk score (all subjects), cerebrovascular accidents, any cardiovascular disease, fasting blood glucose (men only) and type 2 diabetes. Proportion of short telomeres may more closely reflect cellular senescence of a subset of circulating leukocytes and vascular aging than mean telomere length, as has been suggested previously. 12, 13 Indeed, in a study concerning 274 Danish twin pairs, the proportion of shortest telomeres was a better predictor of mortality than mean telomere length. 16 Accordingly, we recently reported that the proportion of shortest telomeres was a better predictor than mean telomere length of progression of renal disease in patients with type 1 diabetes. 10 Telomere length and disease during follow-up We noticed a negative association between mean telomere length and incidence of ischemic heart disease during follow-up in men and with any cardiovascular disease in the whole study group, which is in agreement with previous observations of Figure 1 The mean telomere length and age in males and females. Slope of the solid line indicates the annual telomere-shortening rate in males (telomere log mean change À0.22, 95% CI À0.34, À0.11) and females (telomere log mean change À0.08, 95% CI À0.17, 0.01, per 10-year difference, not significant, P ¼ 0.06). Figure 2 Telomere length and proportion of short telomeres (shorter than 5 kb) in males and females.
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Telomere length in the LIFE study F Fyhrquist et al associations of short telomeres with coronary artery disease 17 and premature myocardial infarction. 15 Shorter telomeres in cardiovascular diseases may reflect the cumulative burden of inflammatory mechanisms and oxidative stress, 18 associated with atherosclerosis and vascular aging.
Telomere length, BMI, smoking and blood pressure
We were unable to demonstrate significant correlations between telomere length or proportion of short telomeres, and BMI, smoking, systolic blood pressure or pressure. In contrast with our observations, two studies on healthy female twins aged 18-75 years, from the St Thomas' (Twins UK) Twin Registry, showed that short telomeres were associated with BMI and smoking. 19, 20 Similar observations were recently made in young (mean age 31.4-37.4 years) whites and African Americans participating in the Bogalusa Heart Study. 21 Associations between BMI, smoking and telomere length may be obscured by several factors known to affect telomere length, Telomere length in the LIFE studyincluding gender, age and cardiovascular disease. Thus, the subjects studied by us were elderly (mean age 67, range 55-80 years) and had two or more cardiovascular risk factors, including LVH and hypertension. Consistent with our findings, other investigators have also failed to demonstrate a significant association between telomere attrition and BMI, 3, 8, 22 smoking 22, 23 or pulse pressure. 23 Several explanations for such apparent lack of consensus may be offered. 24 For instance, telomere length varies individually and is under genetic control. 25 Further, variability of telomere length may be caused by influences of diet and physical activity, 26 psychological stress 27 and various diseases. [5] [6] [7] [8] 15, 16, [22] [23] [24] Importantly, a recent report stated that in 850 Framingham Heart Telomere length in the LIFE studyStudy participants, leukocyte telomere length was positively associated with left ventricular mass and wall thickness, especially in participants with hypertension. 28 If applicable to the LIFE study participants, this observation may partly explain some of the above-mentioned discrepancies, as all of our patients had both hypertension and LVH. However, we failed to show associations of either Cornell product or Sokolow-Lyon voltage index with telomere length (unpublished observation). This may be due to the well-known weakness of these criteria to reliably assess the degree of LVH.
Telomere length and prediction of cardiovascular events Telomere length was predictive of new angina pectoris and any cardiovascular disease taken together, but not of cardiovascular or total mortality, myocardial infarction or stroke as individual outcomes. This may be partly explained by the low numbers of cardiovascular death and stroke during follow-up in this study population. Moreover, antihypertensive treatment might have modified the predictive power of telomere length at baseline. In fact, we noticed in hypertensive patients with type 1 diabetes that those treated with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker had longer telomeres than patients receiving either a b blocker or a calcium channel blocker. 10 Strengths and limitations of this study The strengths of this study were the following: first, the relatively large number of participants; second, all subjects were carefully examined and findings prospectively recorded; third, end points were adjudicated by an endpoint committee; and fourth, the use of a reliable Southern blot 10, 22 method for the measurement of telomere length. An additional strength was that all subjects belonged to an ethnically homogenous Finnish population. The limitations of this study were its character of a cross-sectional post hoc study, and the lack of an age-matched control group.
Conclusions
We have shown in a high-risk middle aged to elderly hypertensive population with LVH that leukocyte telomere length was associated with ischemic heart disease in men and transient ischemic attack in women, and that a high proportion of short telomeres was related to increased cardiovascular risk and type 2 diabetes. Short telomere length was predictive of the combination of any cardiovascular disease during follow-up. The association of telomere length with cardiovascular risk and diabetes supports the concept that short telomeres are markers of cardiovascular aging and risk.
